A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine

International Journal for Parasitology

Volumn 43, Issue 6, 2013, Pages 503-514

  Nagel, Andreas ^a   Prado, Monica ^a   Heitmann, Anna ^a   Tartz, Susanne ^a   Jacobs, Thomas ^a   Deschermeier, Christina ^a   Helm, Susanne ^a   Stanway, Rebecca ^b   Heussler, Volker ^b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Double attenuation; Genetically attenuated parasites; Late liver stage attenuation; Malaria; Plasmodium liver stage; Pore forming toxin

Indexed keywords

BACTERIAL TOXIN; CLOSTRIDIUM PERFRINGENS TOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MALARIA VACCINE; PROTOZOAL PROTEIN; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG;

IMMUNE RESPONSE; MALARIA; PARASITE; TOXIN; VACCINE; VIRULENCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CELL DEATH; CELL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOPLASM; DRUG SAFETY; FEMALE; GENE INACTIVATION; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; INFECTION PREVENTION; INFECTION SENSITIVITY; LIVER CELL; MALARIA; MEMBRANE RUPTURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM; PROTEIN EXPRESSION; PROTEIN SECRETION; SPOROZOITE;

ACIDOSIS, LACTIC; ANIMALS; BACTERIAL TOXINS; BLOOD; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKOUT TECHNIQUES; GENES, ESSENTIAL; GENES, PROTOZOAN; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM BERGHEI; PYRUVATE DEHYDROGENASE (LIPOAMIDE); SURVIVAL ANALYSIS; VACCINES, ATTENUATED;

BACTERIA (MICROORGANISMS); PLASMODIUM BERGHEI; PLASMODIUM PARASITES; RODENTIA;

EID: 84876319647     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2013.01.010     Document Type: Article

References (54)

1. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmuller B., Issifou S., Kremsner P.G., Sacarlal J., Aide P., Lanaspa M., Aponte J.J., Nhamuave A., Quelhas D., Bassat Q., Mandjate S., Macete E., Alonso P., Abdulla S., Salim N., Juma O., Shomari M., Shubis K., Machera F., Hamad A.S., Minja R., Mtoro A., Sykes A., Ahmed S., Urassa A.M., Ali A.M., Mwangoka G., Tanner M., Tinto H., D'Alessandro U., Sorgho H., Valea I., Tahita M.C., Kabore W., Ouedraogo S., Sandrine Y., Guiguemde R.T., Ouedraogo J.B., Hamel M.J., Kariuki S., Odero C., Oneko M., Otieno K., Awino N., Omoto J., Williamson J., Muturi-Kioi V., Laserson K.F., Slutsker L., Otieno W., Otieno L., Nekoye O., Gondi S., Otieno A., Ogutu B., Wasuna R., Owira V., Jones D., Onyango A.A., Njuguna P., Chilengi R., Akoo P., Kerubo C., Gitaka J., Maingi C., Lang T., Olotu A., Tsofa B., Bejon P., Peshu N., Marsh K., Owusu-Agyei S., Asante K.P., Osei-Kwakye K., Boahen O., Ayamba S., Kayan K., Owusu-Ofori R., Dosoo D., Asante I., Adjei G., Chandramohan D., Greenwood B., Lusingu J., Gesase S., Malabeja A., Abdul O., Kilavo H., Mahende C., Liheluka E., Lemnge M., Theander T., Drakeley C., Ansong D., Agbenyega T., Adjei S., Boateng H.O., Rettig T., Bawa J., Sylverken J., Sambian D., Agyekum A., Owusu L., Martinson F., Hoffman I., Mvalo T., Kamthunzi P., Nkomo R., Msika A., Jumbe A., Chome N., Nyakuipa D., Chintedza J., Ballou W.R., Bruls M., Cohen J., Guerra Y., Jongert E., Lapierre D., Leach A., Lievens M., Ofori-Anyinam O., Vekemans J., Carter T., Leboulleux D., Loucq C., Radford A., Savarese B., Schellenberg D., Sillman M., Vansadia P. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875.
2. Aly A.S., Mikolajczak S.A., Rivera H.S., Camargo N., Jacobs-Lorena V., Labaied M., Coppens I., Kappe S.H. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol. 2008, 69:152-163.
3. Annoura T., Ploemen I.H., van Schaijk B.C., Sajid M., Vos M.W., van Gemert G.J., Chevalley-Maurel S., Franke-Fayard B.M., Hermsen C.C., Gego A., Franetich J.F., Mazier D., Hoffman S.L., Janse C.J., Sauerwein R.W., Khan S.M. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012, 30:2662-2670.
4. Bano N., Romano J.D., Jayabalasingham B., Coppens I. Cellular interactions of Plasmodium liver stage with its host mammalian cell. Int. J. Parasitol. 2007, 37:1329-1341.
5. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9:451-462.
6. Chakravarty S., Cockburn I.A., Kuk S., Overstreet M.G., Sacci J.B., Zavala F. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 2007, 13:1035-1041.
7. Clyde D.F., McCarthy V.C., Miller R.M., Woodward W.E. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 1975, 24:397-401.
8. Dang T.X., Hotze E.M., Rouiller I., Tweten R.K., Wilson-Kubalek E.M. Prepore to pore transition of a cholesterol-dependent cytolysin visualized by electron microscopy. J. Struct. Biol. 2005, 150:100-108.
9. Deschermeier C., Hecht L.S., Bach F., Rutzel K., Stanway R.R., Nagel A., Seeber F., Heussler V.T. Mitochondrial lipoic acid scavenging is essential for Plasmodium berghei liver stage development. Cell. Microbiol. 2012, 14:416-430.
10. Douradinha B., van Dijk M.R., Ataide R., van Gemert G.J., Thompson J., Franetich J.F., Mazier D., Luty A.J., Sauerwein R., Janse C.J., Waters A.P., Mota M.M. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int. J. Parasitol. 2007, 37:1511-1519.
11. Falae A., Combe A., Amaladoss A., Carvalho T., Menard R., Bhanot P. Role of Plasmodium berghei cGMP-dependent protein kinase in late liver stage development. J. Biol. Chem. 2010, 285:3282-3288.
12. Foth B.J., Stimmler L.M., Handman E., Crabb B.S., Hodder A.N., McFadden G.I. The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase complex, which is located in the apicoplast. Mol. Microbiol. 2005, 55:39-53.
13. Franke-Fayard B., Trueman H., Ramesar J., Mendoza J., van der Keur M., van der Linden R., Sinden R.E., Waters A.P., Janse C.J. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 2004, 137:23-33.
14. Friesen J., Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011, 29:7002-7008.
15. Graewe S., Retzlaff S., Struck N., Janse C.J., Heussler V.T. Going live: a comparative analysis of the suitability of the RFP derivatives RedStar, mCherry and tdTomato for intravital and in vitro live imaging of Plasmodium parasites. Biotechnol. J. 2009, 4:895-902.
16. Graewe S., Rankin K.E., Lehmann C., Deschermeier C., Hecht L., Froehlke U., Stanway R.R., Heussler V. Hostile takeover by Plasmodium: reorganization of parasite and host cell membranes during liver stage egress. PLoS Pathog. 2011, 7:e1002224.
17. Graewe S., Stanway R.R., Rennenberg A., Heussler V.T. Chronicle of a death foretold: Plasmodium liver stage parasites decide on the fate of the host cell. FEMS Microbiol. Rev. 2012, 36:111-130.
18. Gueirard P., Tavares J., Thiberge S., Bernex F., Ishino T., Milon G., Franke-Fayard B., Janse C.J., Menard R., Amino R. Development of the malaria parasite in the skin of the mammalian host. Proc. Natl. Acad. Sci. USA 2010, 107:18640-18645.
19. Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull. W.H.O. 1979, 57(Suppl. 1):165-173.
20. Hafalla J.C., Rai U., Morrot A., Bernal-Rubio D., Zavala F., Rodriguez A. Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites. Eur. J. Immunol. 2006, 36:1179-1186.
21. Haussig J.M., Matuschewski K., Kooij T.W. Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites. Mol. Microbiol. 2011, 81:1511-1525.
22. Helm S., Lehmann C., Nagel A., Stanway R.R., Horstmann S., Llinas M., Heussler V.T. Identification and characterization of a liver stage-specific promoter region of the malaria parasite Plasmodium. PLoS One 2010, 5:e13653.
23. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., Sacci J., de la Vega P., Dowler M., Paul C., Gordon D.M., Stoute J.A., Church L.W., Sedegah M., Heppner D.G., Ballou W.R., Richie T.L. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 2002, 185:1155-1164.
24. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., Li T., Chakravarty S., Gunasekera A., Chattopadhyay R., Li M., Stafford R., Ahumada A., Epstein J.E., Sedegah M., Reyes S., Richie T.L., Lyke K.E., Edelman R., Laurens M.B., Plowe C.V., Sim B.K. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccine 2010, 6:97-106.
25. Ishino T., Chinzei Y., Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol. Microbiol. 2005, 58:1264-1275.
26. Ishino T., Boisson B., Orito Y., Lacroix C., Bischoff E., Loussert C., Janse C., Menard R., Yuda M., Baldacci P. LISP1 is important for the egress of Plasmodium berghei parasites from liver cells. Cell. Microbiol. 2009, 11:1329-1339.
27. Janse C.J., Franke-Fayard B., Mair G.R., Ramesar J., Thiel C., Engelmann S., Matuschewski K., van Gemert G.J., Sauerwein R.W., Waters A.P. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol. Biochem. Parasitol. 2006, 145:60-70.
28. Janse C.J., Ramesar J., Waters A.P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat. Protoc. 2006, 1:346-356.
29. Jobe O., Lumsden J., Mueller A.K., Williams J., Silva-Rivera H., Kappe S.H., Schwenk R.J., Matuschewski K., Krzych U. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J. Infect. Dis. 2007, 196:599-607.
30. Jones S., Portnoy D.A. Characterization of Listeria monocytogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect. Immun. 1994, 62:5608-5613.
31. Jones S., Preiter K., Portnoy D.A. Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen. Mol. Microbiol. 1996, 21:1219-1225.
32. Khan S.M., Janse C.J., Kappe S.H., Mikolajczak S.A. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 2012, 23:908-916.
33. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 2007, 75:3758-3768.
34. Mikolajczak S.A., Sacci J.B., De La Vega P., Camargo N., Vanbuskirk K., Krzych U., Cao J., Jacobs-Lorena M., Cowman A.F., Kappe S.H. Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. Cell. Microbiol. 2011, 13:1250-1260.
35. Mueller A.K., Camargo N., Kaiser K., Andorfer C., Frevert U., Matuschewski K., Kappe S.H. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. USA 2005, 102:3022-3027.
36. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433:164-167.
37. Nelson L.D., Johnson A.E., London E. How interaction of perfringolysin O with membranes is controlled by sterol structure, lipid structure, and physiological low pH: insights into the origin of perfringolysin O-lipid raft interaction. J. Biol. Chem. 2008, 283:4632-4642.
38. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
39. O'Brien D.K., Melville S.B. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C. perfringens in host tissues. Infect. Immun. 2004, 72:5204-5215.
40. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 2001, 39:1681-1689.
41. Pei Y., Tarun A.S., Vaughan A.M., Herman R.W., Soliman J.M., Erickson-Wayman A., Kappe S.H. Plasmodium pyruvate dehydrogenase activity is only essential for the parasite's progression from liver infection to blood infection. Mol. Microbiol. 2010, 75:957-971.
42. Portnoy D.A., Tweten R.K., Kehoe M., Bielecki J. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect. Immun. 1992, 60:2710-2717.
43. Putrianti E.D., Schmidt-Christensen A., Arnold I., Heussler V.T., Matuschewski K., Silvie O. The Plasmodium serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite. Cell. Microbiol. 2010, 12:725-739.
44. Rosado C.J., Kondos S., Bull T.E., Kuiper M.J., Law R.H., Buckle A.M., Voskoboinik I., Bird P.I., Trapani J.A., Whisstock J.C., Dunstone M.A. The MACPF/CDC family of pore-forming toxins. Cell. Microbiol. 2008, 10:1765-1774.
45. Scheller L.F., Wirtz R.A., Azad A.F. Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei. Infect. Immun. 1994, 62:4844-4847.
46. Silvie O., Goetz K., Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog. 2008, 4:e1000086.
47. Southern J.A., Young D.F., Heaney F., Baumgartner W.K., Randall R.E. Identification of an epitope on the P and V proteins of simian virus 5 that distinguishes between two isolates with different biological characteristics. J. Gen. Virol. 1991, 72(Pt 7):1551-1557.
48. Sturm A., Amino R., van de Sand C., Regen T., Retzlaff S., Rennenberg A., Krueger A., Pollok J.M., Menard R., Heussler V.T. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 2006, 313:1287-1290.
49. Tarun A.S., Dumpit R.F., Camargo N., Labaied M., Liu P., Takagi A., Wang R., Kappe S.H. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J. Infect. Dis. 2007, 196:608-616.
50. Tilley S.J., Saibil H.R. The mechanism of pore formation by bacterial toxins. Curr. Opin. Struct. Biol. 2006, 16:230-236.
51. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., van Dooren M.W., van Schaijk B., van Gemert G.J., Sauerwein R.W., Mota M.M., Waters A.P., Janse C.J. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl. Acad. Sci. USA 2005, 102:12194-12199.
52. VanBuskirk K.M., O'Neill M.T., De La Vega P., Maier A.G., Krzych U., Williams J., Dowler M.G., Sacci J.B., Kangwanrangsan N., Tsuboi T., Kneteman N.M., Heppner D.G., Murdock B.A., Mikolajczak S.A., Aly A.S., Cowman A.F., Kappe S.H. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl. Acad. Sci. USA 2009, 106:13004-13009.
53. Vaughan A.M., O'Neill M.T., Tarun A.S., Camargo N., Phuong T.M., Aly A.S., Cowman A.F., Kappe S.H. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol. 2009, 11:506-520.
54. Yu M., Kumar T.R., Nkrumah L.J., Coppi A., Retzlaff S., Li C.D., Kelly B.J., Moura P.A., Lakshmanan V., Freundlich J.S., Valderramos J.C., Vilcheze C., Siedner M., Tsai J.H., Falkard B., Sidhu A.B., Purcell L.A., Gratraud P., Kremer L., Waters A.P., Schiehser G., Jacobus D.P., Janse C.J., Ager A., Jacobs W.R., Sacchettini J.C., Heussler V., Sinnis P., Fidock D.A. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008, 4:567-578.